IRADIMED CORP (IRMD) Form 8-K — Oct 30, 2026
Iradimed reported record Q3 2026 revenue of $24.2 million, up 14% year-over-year, with GAAP diluted EPS of $0.51 (+17%) and non-GAAP EPS of $0.55, driven by the ramp of its new 3870 MR IV pump and record monitor bookings. Management guided Q4 2026 revenue to $25.0-$26.5 million, reaching a $100 million annual revenue run rate, and narrowed full-year 2026 revenue guidance to $91.6-$93.1 million. The board also declared a regular quarterly cash dividend of $0.20 per share payable November 27, 2026.
Key figures
- Eps
- 0.51
- Revenue
- 24203000
- Guidance
- Q4 2026 revenue $25.0M-$26.5M, GAAP diluted EPS $0.53-$0.57, non-GAAP EPS $0.57-$0.61; FY2026 revenue $91.6M-$93.1M (narrowed from $91.0M-$96.0M), GAAP EPS $1.90-$1.94, non-GAAP EPS $2.07-$2.11
- Net Income
- 6506000
- Total Debt
- 0
- Revenue Yoy
- 0.14
- Total Assets
- 121070000
- Cash Position
- 63288000
- Shares Outstanding
- 12787000
- Gross margin q3
- 76%
- Free cash flow q3
- 6784000
- Nine month revenue
- 66648000
- Nine month net income
- 17542000
- Non gaap net income q3
- 7122000
- Operating cash flow q3
- 6996000
- Non gaap diluted eps q3
- 0.55
- Quarterly dividend per share
- 0.2
- Pump channel bookings growth yoy
- 45%
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.